Revolutionizing Diagnostic Testing: Ce.B.Tec.’s Breakthrough in Portable Biosensors

Ce.B.Tech continues the development of its innovative solutions and celebrates with another publication in the Journal of “Exploration of Digital Health Technologies” titled “Systems for classifying antibody concentration against severe acute respiratory syndrome coronavirus 2 S1 spike antigen with automatic quick response generation for integration with health passports”.

In the wake of the COVID-19 pandemic, the need for rapid and accurate diagnostic testing has never been more critical. Ce.B.Tec. P.C. and their pioneering research partners specializing in advanced diagnostics and point-of-care solutions have introduced a groundbreaking system for classifying antibody concentration against the SARS-CoV-2 S1 spike antigen. This innovative method provides faster and more accurate results and opens doors to a myriad of applications, including the development of electronic passports and targeted prevention strategies.

Our team’s system is a biosensor technology based on immobilized engineered SK-N-SH neuroblastoma cells, capable of detecting immunoglobulin G (IgG) antibodies against the SARS-CoV-2 S1 spike antigen. Unlike traditional methods, this system offers faster and more accurate results, thanks to its portable, ultra-rapid, and sensitive biosensor that transmits real-time measurements to a smartphone. By leveraging a smartphone application, historical and current individual data can be encoded into a widely accepted quick response (QR) code, enabling continuous updates to match a person’s status.

The implications of this innovation extend far beyond individual antibody assessment. Our system has the potential to revolutionize population-wide surveillance of vaccination efficiency and facilitate the implementation of cross-border digital health services. By providing a user-friendly and secure method for assessing antibody levels, it empowers individuals to make informed decisions about booster vaccine doses. It reduces the need for stringent social distancing measures.

Ce.B.Tec.’s expertise in Bioelectric Biosensors technologies and Molecular Identification through Membrane Engineering positions them as leaders in the field of portable diagnostic and analytical devices. Their success in developing susceptible, fast, and affordable diagnostic tests has been recognized with prestigious awards, including the Johnson & Johnson Idea Incubator Award and the National Defense Innovation Challenge Prize.

As it continues to innovate and expand its portfolio of national and international patents, its strategic roadmap involves diversifying into other diagnostic system technologies. By prioritizing low-cost prototype products and investing in research and development, they aim to establish a solid foundation for future growth and success in various sectors, including agri-food, environment, medicine, and biotechnology. We invite you to join them on their journey to revolutionize diagnostic testing and shape the future of healthcare with their cutting-edge technologies and specialized services.

You can access the publication here:


Scroll to Top